Public Policy – Not The Economy – Must Be Biotech Sector’s Focus, BIO CEO Says
This article was originally published in The Pink Sheet Daily
The capital crisis will pass, Greenwood says, but the need to engage on public policy will remain paramount. A sign of a mature industry?
You may also be interested in...
FOB pathway would create only $6.35 billion in savings, according to the budget, down from the $9.24 billion projected in February.
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.